Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD — Stella

Home/Alzheimer Disease, Early Onset/

View on ClinicalTrials.gov

Recruiting

Back to Alzheimer Disease, Early Onset trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

Cedars-Sinai Medical Center, Los Angeles, California

Memory and Aging Program, Butler Hospital, Providence, Rhode Island

Key details

Phase

Early testing

Sponsor

Butler Hospital

Collaborators

Alzheimer's Association, Brown University

Enrollment target

~35 participants

Started

December 2021

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

50 Years – 85 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.